| Date | Title | | | 12/21/04 | indiplon IR NDA (New Drug Application) to Be Reformatted Due to Difficulties in Accessing Portions of the Electronic NDA| SAN DIEGO, Dec. 21 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the U.S. Food and Drug Administration
(FDA) has not accepted the Company's NDA for indiplon immediate release (IR)
due to difficulties encountered in navigating the electronic NDA. Neurocrine
is working to resolve the issues relating to the navigation of the electronic
filing and to minimize any impact on the expected timelines for approval and
launch of indiplon. The indiplon mo... |
|  | | 12/14/04 | Neurocrine Biosciences Announces Initiation of Phase I Trial With CRF1 Antagonist for Anxiety and Depression| SAN DIEGO, Dec 14, 2004 /PRNewswire-FirstCall via COMTEX/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that its partner GlaxoSmithKline (GSK) has
initiated a Phase I clinical trial with a lead Corticotropin Releasing Factor
1 (CRF1) receptor antagonist compound. The Phase I clinical trial is a
double-blind, randomized, placebo controlled, single dose study to evaluate
the safety and pharmacokinetics (PK) of a range of escalating doses of this
compound in healthy voluntee... |
| | | 11/22/04 | Neurocrine Submits New Drug Application (NDA) for Indiplon Modified Release Tablets for the Treatment of Insomnia| SAN DIEGO, Calif., Nov. 22 /PRNewswire-FirstCall/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced that it has submitted a New Drug
Application (NDA) to the U.S. Food and Drug Administration (FDA) for
regulatory approval of indiplon modified release tablets for the treatment of
insomnia. The application contains safety and efficacy results from 8 Phase
III clinical trials with indiplon modified release conducted in adult and
elderly patients with transient and chronic insomnia. The... |
| | | 11/15/04 | Neurocrine Biosciences to Present at SG Cowen & Company's 5th Annual Global Health Care Conference| SAN DIEGO, Nov 15, 2004 /PRNewswire-FirstCall via COMTEX/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will present at SG Cowen &
Company's 5th Annual Global Health Care Conference at The Hilton Geneva,
Switzerland tomorrow, Tuesday, November 16, 2004 at 8:35AM Central European
Time (CET)/Monday, Nov. 15, 2004 at 11:35PM Pacific Standard Time (PST). The
presentation will be simultaneously webcast and can be accessed on the
Company's website at http:/... |
| | | 11/10/04 | Neurocrine Biosciences Announces Licensing Agreement With Almirall for Parkinson's Disease| SAN DIEGO, Nov 10, 2004 /PRNewswire-FirstCall via COMTEX/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that it has entered into a licensing agreement
with Almirall Prodesfarma, S.A., the leading Spanish multinational
pharmaceutical company which is based in Barcelona, Spain, for A2A receptor
antagonists for Parkinson's Disease. Under the terms of the agreement,
Almirall and Neurocrine will share territorial rights and registration data
from their respective territories f... |
| | | 11/05/04 | Neurocrine Biosciences Presents at CIBC World Markets 15th Annual Health Care Conference| The Presentation Will Be Webcast Monday, November 8, 2004 SAN DIEGO, Nov 5, 2004 /PRNewswire-FirstCall via COMTEX/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will present at the CIBC World
Markets 15th Annual Health Care Conference on Monday, November 8, 2004 at
11:30AM Eastern Standard Time (EST) / 8:30AM Pacific Standard Time (PST). The
presentation will be simultaneously webcast and can be accessed on the
Company's website at http://www.neurocrine.c... |
| | | 11/01/04 | Neurocrine Biosciences Reports Third Quarter 2004 Results| Neurocrine Receives Milestones for Successful Long Term and Sleep Maintenance
Results With Indiplon
SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced its financial results for the quarter ended
September 30, 2004. For the third quarter, the Company reported a net loss of
$1.6 million, or $0.05 per share compared with a net loss of $9.8 million, or
$0.31 per share, for the same period last year. For th... |
| | | 11/01/04 | Reminder - Neurocrine Biosciences Announces Webcast and Conference Call to Present Third Quarter 2004 Financial Results| SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report third quarter 2004
financial results after the Nasdaq market closes Monday, November 1, 2004.
Neurocrine will also host a live conference call and webcast to discuss the
third quarter results and provide a Company update on Monday afternoon,
November 1, 2004 at 5:00PM Eastern Standard Time (EST), 2:00PM Pacific
Standard Time (PST). Participants may access th... |
| | | 10/25/04 | Neurocrine Biosciences Announces Initiation of Phase I Trial With Urocortin 2 for Congestive Heart Failure| SAN DIEGO, Oct 25, 2004 /PRNewswire-FirstCall via COMTEX/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today initiation of the Company's Phase I clinical
trial with its proprietary compound, urocortin 2, to evaluate the safety,
pharmacokinetics (PK), and pharmacodynamics (PD) of urocortin 2 in healthy
volunteers and expects to initiate a Phase II clinical study in patients with
mild to moderate congestive heart failure in early 2005.
"We are pleased to advance this compound... |
| | | 10/21/04 | Neurocrine Biosciences Announces Webcast and Conference Call to Present Third Quarter 2004 Financial Results| SAN DIEGO, Oct. 21 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report third quarter 2004
financial results after the Nasdaq market closes Monday, November 1, 2004.
Neurocrine will also host a live conference call and webcast to discuss the
third quarter results and provide a Company update on Monday afternoon,
November 1, 2004 at 5:00PM Eastern Standard Time (EST), 2:00PM Pacific
Standard Time (PST). Participants may access t... |
| | | 10/19/04 | Neurocrine Submits New Drug Application (NDA) for Indiplon Immediate Release Capsules for the Treatment of Insomnia| SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced that it has submitted a New Drug Application (NDA) to
the U.S. Food and Drug Administration (FDA) for regulatory approval of
indiplon immediate release capsules for the treatment of insomnia. The
application contains safety and efficacy results from seven Phase III clinical
trials with indiplon immediate release conducted in adult and elderly patients
with transient and chronic insomnia. Ne... |
| | | 09/27/04 | Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference| SAN DIEGO, Sep 27, 2004 /PRNewswire-FirstCall via COMTEX/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will present at the UBS Global
Life Sciences Conference at the Grand Hyatt in New York tomorrow, Tuesday,
September 28, 2004 at 12:30pm EDT/9:30am PDT. The presentation will be
simultaneously webcast and can be accessed on the Company's website at
http://www.neurocrine.com.
Gary Lyons, President and Chief Executive Officer of Neurocrine will
report... |
| | | 09/13/04 | Neurocrine Biosciences to Present at Bear Stearns 17th Annual Healthcare Conference| Presentation Will be Webcast Today at 11:00am EDT
SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will present at Bear Stearns
17th Annual Healthcare Conference in New York today, Monday, September 13,
2004 at 11:00am EDT/8:00am PDT. The presentation will be simultaneously
webcast and can be accessed on the Company's website at
http://www.neurocrine.com . Gary Lyons, President and Chief Executive Officer... |
| | | 09/09/04 | Neurocrine Reports Positive Phase III Efficacy and Safety Results With Indiplon Modified Release in Treating Elderly Patients| Neurocrine Is on Track to File NDAs for Both Indiplon IR and MR
SAN DIEGO, Sept. 9 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced positive efficacy and safety results from the
Company's Phase III clinical trial with indiplon modified release 15 mg in
229 elderly patients with chronic insomnia. Neurocrine is on track to submit
its two New Drug Applications (NDAs) for the immediate and modified release
formulations of indiplon beginning in October... |
| | | 09/07/04 | Neurocrine Biosciences to Present at BioCentury's NewsMakers in the Biotech Industry Investment Conference| SAN DIEGO, Sept. 7 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will present at the 11th
Anniversary of BioCentury's NewsMakers in the Biotech Industry Investment
Conference at the Millennium Broadway Hotel and Conference Center in New York
on Thursday, September 9, 2004 at 4:00pm EDT/1:00pm PDT. The presentation
will be simultaneously webcast and can be accessed on the Company's website at
http://www.neurocrine.com . Gary Ly... |
| | | 07/29/04 | Reminder - Neurocrine Biosciences Announces Conference Call and Webcast to
Present Second Quarter 2004 Financial Results and Company Update| SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report second quarter
2004 financial results after the Nasdaq market closes Wednesday, July 28,
2004. Neurocrine will also host a live conference call and Webcast to discuss
its second quarter financial results and Company update Thursday morning,
July 29, 2004 at 11:00 AM Eastern Daylight Time (EDT) / 8:00 AM Pacific
Daylight Time (PDT). Participants may access ... |
| | | 07/28/04 | Neurocrine Biosciences Reports Second Quarter 2004 Results| Neurocrine Receives Milestone From Pfizer for Achievement of Long Term
Efficacy Results With Indiplon SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced its financial results for the quarter ended
June 30, 2004. For the second quarter, the Company reported a net loss of
$11.1 million, or $0.31 per share compared with a net loss of $10.2 million,
or $0.33 per share, for the same period last year. For the six... |
| | | 07/19/04 | Neurocrine Biosciences Announces Conference Call and Webcast to Present Second
Quarter 2004 Financial Results and Company Update| SAN DIEGO, July 19 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report second quarter
2004 financial results after the Nasdaq market closes Wednesday, July 28,
2004. Neurocrine will also host a live conference call and Webcast to discuss
its second quarter financial results and Company update Thursday morning,
July 29, 2004 at 11:00 AM Eastern Daylight Time (EDT) / 8:00 AM Pacific
Daylight Time (PDT). Participants may access ... |
| | | 07/15/04 | Neurocrine Reports Progress on Indiplon Registration| SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Neurocrine Biosciences
(Nasdaq: NBIX) said today that a review of more than 70 indiplon studies
involving more than 7,000 patients comprising the most comprehensive and
innovative insomnia program ever conducted has been completed. As a result of
this review, Neurocrine has announced the following:
* Indiplon new drug applications (NDAs) in adult and elderly patients
are planned to be submitted to the U.S. Food and Drug Administ... |
| | | 06/09/04 | Neurocrine Biosciences Announces the Appointment of Corinne H. Lyle to its
Board of Directors| SAN DIEGO, June 9 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that it has elected Corinne H. Lyle to its
Board of Directors effective immediately. Lyle is the current Corporate Vice
President, Chief Financial Officer and Treasurer of Edwards Lifesciences
Corporation. "We are fortunate to have a person of Corinne Lyle's caliber join our
Board of Directors. Corinne brings operational finance and investment banking
experience to the Board havin... |
| | | 06/07/04 | Neurocrine Biosciences Presents Six Indiplon Studies at the Associated
Professional Sleep Societies (APSS) Meeting| Results Demonstrate Indiplon Significantly Improves Sleep Initiation and
Sleep Maintenance PHILADELPHIA, June 7 /PRNewswire-FirstCall/ -- Neurocrine Biosciences,
Inc. (Nasdaq: NBIX) announced today that six studies from Phase I, II and III
clinical trials with both formulations of indiplon will be presented at the
Associated Professional Sleep Societies (APSS) Meeting,
June 5-10, 2004 in Philadelphia, PA. The studies demonstrate that two
formulations of ... |
| | | 05/06/04 | Neurocrine Biosciences Announces Indiplon Modified Release Demonstrates Lack
of Respiratory Side Effects| Data Presented at the American Psychiatric Association (APA) Meeting
NEW YORK, May 6 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today results from two Phase I studies demonstrating
that indiplon modified release does not effect respiratory functioning in
healthy subjects or those with mild-to-moderate chronic obstructive pulmonary
disease (COPD). These results were presented today at the 157th annual
meeting of the American Psychiatric Association... |
| | | 05/06/04 | Neurocrine Biosciences Presents Phase III Data at the American Psychiatric
Association (APA) Meeting| Results Demonstrate Both Formulations of Indiplon are Safe and Effective in
Treating Patients With Chronic and Transient Insomnia NEW YORK, May 6 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that four studies were presented this week at
the 157th annual meeting of the American Psychiatric Association (APA)
demonstrating the efficacy and safety of both formulations of indiplon,
immediate release and modified release, in treating patie... |
| | | 05/04/04 | Neurocrine Biosciences Announces Study Showing Indiplon
Immediate Release Safe for Middle of the Night Dosing Without
Next Day Residual Effects| Data Presented at the American Psychiatric Association (APA) Meeting
NEW YORK, May 4 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced results from a study in healthy volunteers presented
today that shows that indiplon immediate release when taken in the middle of
the night (MOTN) is safe and well tolerated without evidence of next day
residual effects. These results were presented at the 157th annual meeting of
the American Psychiatric Association (APA)... |
| | | 05/03/04 | Neurocrine Biosciences Presents at the Deutsche Bank Securities 29th Annual
Health Care Conference| The Presentation Will Be Webcast Tuesday, May 4, 2004
SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will present at the Deutsche
Bank Securities 29th Annual Health Care Conference tomorrow, Tuesday, May 4,
2004 at 9:30 AM Eastern Daylight Time (EDT) and 6:30 AM Pacific Daylight Time
(PDT). The presentation will be simultaneously webcast and can be accessed on
the Company's website at http://www.neurocrine.com ... |
| | | 05/03/04 | Neurocrine Biosciences Reports First Quarter 2004 Results| Company Will Host a Conference Call and Webcast Today, Monday, May 3, 2004 SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced its financial results for the quarter ended
March 31, 2004. For the first quarter, the Company reported a net loss of
$12.4 million, or $0.35 per share compared with a net loss of $13.4 million,
or $0.43 per share, for the same period in 2003. Revenues for the first quarter of 2004 were $16.9 million compar... |
| | | 04/30/04 | Reminder - Neurocrine Biosciences Sets New Date for First Quarter 2004
Earnings Conference Call and Webcast| Conference Call and Webcast Rescheduled for Monday, May 3, 2004
SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company is rescheduling its first
quarter 2004 earnings announcement and conference call in light of the timing
and potential conflicts with the Deutsche Bank Healthcare Conference.
Neurocrine will now release its first quarter 2004 financial results on Monday
morning, May 3, 2004 at 7:00 AM Eastern Time (ET)... |
| | | 04/26/04 | Neurocrine Biosciences Sets New Date for First Quarter 2004 Earnings
Conference Call and Webcast| Conference Call and Webcast Rescheduled for Monday, May 3, 2004
SAN DIEGO, April 26 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company is rescheduling its first
quarter 2004 earnings announcement and conference call in light of the timing
and potential conflicts with the Deutsche Bank Healthcare Conference.
Neurocrine will now release its first quarter 2004 financial results on Monday
morning, May 3, 2004 at 7:00 AM Eastern Time (ET)... |
| | | 04/22/04 | Neurocrine Biosciences Announces Conference Call and Webcast to Present
First Quarter 2004 Financial Results| Management Will Also Provide Company Update
SAN DIEGO, April 22 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report first quarter 2004
financial results after the Nasdaq market closes Tuesday, May 4, 2004.
Neurocrine will also host a live conference call and Webcast to discuss its
first quarter financial results and provide a Company update Wednesday
morning, May 5, 2004 at 11:00 AM Eastern Daylight Time (EDT) / 8:00 AM Pa... |
| | | 04/07/04 | Neurocrine Reports Two Additional Phase III Trials Demonstrating Indiplon Is
Safe and Effective in Treating Elderly Patients With Difficulties
Initiating and Maintaining Sleep| Results in Over 7000 Subjects to Date Support Efficacy and Safety for Sleep
Initiation, Sleep Maintenance, and Long-Term Treatment SAN DIEGO, April 7 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced preliminary positive results from two of the
Company's Phase III clinical trials. The trials reported today evaluated the
two formulations of indiplon, immediate release and modified release, in
elderly patients with chronic insomnia. Neurocr... |
| | | 03/24/04 | Neurocrine's 'SLEEP' Study Demonstrates Highly Positive
Long-Term Efficacy Results With Indiplon Modified Release| Patients Gained Up to 90 Minutes of Total Sleep Time - Sustained Throughout
Study SAN DIEGO, March 24 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced a second long term Phase III trial with highly
positive efficacy results from its three month pivotal study, referred to as
"SLEEP," the Study of Long-term Efficacy and Safety of indiplon modified
release in Primary (Chronic) Insomnia patients. Preliminary results
... |
| | | 03/24/04 | Neurocrine's 'RESTFUL' Study Demonstrates Highly Positive
Long-Term Efficacy Results with Indiplon Immediate Release| Sustained Effects on Sleep Initiation and Sleep Quality Over Entire
Treatment Period SAN DIEGO, March 24 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced positive results from the pivotal long term
efficacy and safety Phase III "RESTFUL" trial with indiplon immediate release
in patients with chronic insomnia, achieving highly statistically significant
results in sleep initiation and sleep quality that were sustained ov... |
| | | 03/23/04 | Neurocrine Biosciences to Present at the Wells Fargo Securities
Healthcare Conference| The Presentation Will Be Webcast Wednesday, March 24, 2004
SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will present at the Wells
Fargo Securities Healthcare Conference at the St. Regis Hotel in New York City
tomorrow, Wednesday, March 24, 2004 at 12:00PM Eastern Standard Time and
9:00AM Pacific Standard Time. The presentation will be simultaneously webcast
and can be accessed on the Company's website at h... |
| | | 03/16/04 | Neurocrine and Wyeth Satisfy Hart-Scott-Rodino Requirements for the
Acquisition of Indiplon Royalty Stream| SAN DIEGO, March 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced the expiration of the waiting period required
under the Hart-Scott-Rodino Antitrust Improvements Act in connection with the
purchase from Wyeth (NYSE: WYE) all of Wyeth's financial interest in indiplon,
Neurocrine's late stage Phase III compound for the treatment of insomnia. In
addition to the requirements of the Hart-Scott-Rodino Act being met, Wyeth's
Board of Directors has also ap... |
| | | 03/09/04 | Neurocrine Biosciences to Present at the SG Cowen 24th
Annual Health Care Conference| SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will present at the SG Cowen
24th Annual Health Care Conference at the Boston Marriott Copley Place
tomorrow, Wednesday, March 10, 2004. The conference will host two
presentations and will take place at 1:15pm EST/10:15am PST and 2:15pm
EST/11:15am PST. The presentations will be simultaneously webcast with slides
and can be accessed on the Company's website at http:/... |
| | | 03/03/04 | Neurocrine Biosciences Presents at the Lehman Brothers Seventh Annual Global
Healthcare Conference| SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will present at the Lehman
Brothers Seventh Annual Global Healthcare Conference at Loews Miami Beach
Hotel tomorrow, Thursday, March 4, 2004 at 2:00 PM Eastern Standard Time;
11:00 AM Pacific Standard Time. The presentation will be simultaneously
webcast and can be accessed on the Company's website at
http://www.neurocrine.com . Gary Lyons, President and CEO of ... |
| | | 03/02/04 | Neurocrine Reports Indiplon Effective in Treating Elderly Patients
With Difficulties Maintaining Sleep| Indiplon Modified Release Demonstrates Highly Statistically
Significant Improvement in Sleep Maintenance SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced positive results from its Phase III trial with
the modified release formulation of indiplon, achieving highly statistically
significant results in elderly patients with chronic insomnia who have sleep
maintenance difficulties. Results demonstrated that with indi... |
| | | 03/01/04 | Neurocrine Reports Positive Results for Indiplon in Adults
With Transient Insomnia| Indiplon Modified Release Formulation Demonstrates Statistically
Significant Improvement in Sleep Initiation SAN DIEGO, March 1 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced positive results from its Phase III trial with
the modified release formulation of indiplon, achieving highly statistically
significant results in adults with transient insomnia. The study was a
randomized, double-blind, placebo-controlled, parallel-group, mu... |
| | | 02/26/04 | Neurocrine Biosciences Acquires Wyeth's Indiplon Royalty Stream| Company to Host Conference Call and Webcast Friday, February 27, 2004
SAN DIEGO, Feb. 26 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced it has purchased from Wyeth (NYSE: WYE) all of
Wyeth's financial interest in indiplon, Neurocrine's late stage clinical
development compound for the treatment of insomnia. Neurocrine will now
retain all milestone, royalty and other payments on indiplon commercialization
that would have otherwise been payable to ... |
| | | 02/18/04 | Neurocrine Reports Positive Results for the First Indiplon Phase III Trial In
Elderly Patients With Chronic Insomnia| Immediate Release Formulation Demonstrated Statistically Significant
Improvements in Sleep Initiation and Sleep Quality SAN DIEGO, Feb. 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced positive results from its Phase III clinical
trial with two doses (5 mg and 10 mg) of the immediate release formulation of
indiplon, achieving statistically significant results in elderly patients with
chronic insomnia. Results of the primary endpoin... |
| | | 02/02/04 | Neurocrine Biosciences Presents at the Merrill Lynch Global
Pharmaceutical, Biotechnology and Medical Device Conference| SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will present at the Merrill
Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
entitled "R&D is the Prescription for a Cost Containment Environment" at the
Grand Hyatt in New York tomorrow, Tuesday, February 3, 2004 at 3:35 PM Eastern
Standard Time; 12:35 AM Pacific Standard Time. The presentation will be
simultaneously webcast and can be acces... |
| | | 01/30/04 | Reminder - Neurocrine Biosciences Announces Conference Call and Webcast
to Present Fourth Quarter and Year-End 2003 Financial Results| Company Will Also Provide Update on Clinical Programs
SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report fourth quarter and
year-end 2003 financial results after the Nasdaq market closes Thursday,
January 29, 2004. Neurocrine will also host a live conference call and
Webcast to discuss its year-end financial results and provide a Company update
Friday morning, January 30, 2004 at 11:00 AM Eastern Stand... |
| | | 01/29/04 | Neurocrine Biosciences Reports Fourth Quarter and Year-End 2003 Results| Company Provides Update on Clinical Programs
SAN DIEGO, Jan. 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced its financial results for the fourth quarter
and year ended December 31, 2003. For the three months ended December 31,
2003, the Company reported a net profit of $3.2 million or $0.09 diluted
earnings per share compared to a net loss of $38.8 million or $1.27 per share
for the same period last year. During the 4th quarter, the Company ... |
| | | 01/26/04 | Neurocrine Biosciences Announces Conference Call and Webcast
to Present Fourth Quarter and Year-End 2003 Financial Results| Company Will Also Provide Update on Clinical Programs
SAN DIEGO, Jan. 26 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report fourth quarter and
year-end 2003 financial results after the Nasdaq market closes Thursday,
January 29, 2004. Neurocrine will also host a live conference call and
Webcast to discuss its year-end financial results and provide a Company update
Friday morning, January 30, 2004 at 11:00 AM Eastern Stand... |
| | | 01/12/04 | Neurocrine Biosciences to Present at the 22nd Annual
JPMorgan Healthcare Conference| Presentation Will be Webcast Wednesday, January 14, 2004
SAN DIEGO, Jan. 12 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will be presenting at the
JPMorgan Healthcare Conference in San Francisco at the Westin St. Francis
Hotel on Wednesday afternoon, January 14, 2004 at 4:00PM Pacific Standard Time
and 7:00PM Eastern Standard Time. The presentation will be simultaneously
webcast and can be accessed on the Company's website at
... |
| |
|
